Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Kalinderi, K., Papaliagkas, V., & Fidani, L
PT-141 (Bremelanotide) Research & Scientific Overview Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References PT-141 (Bremelanotide) Molecular Structure & Chemical Properties PT-141 represents a significant milestone in sexual dysfunction research as the first FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder
JCI Insight 7, e159863
The development of further dual GLP-1/GIP receptor agonists seems to be a promising next step in managing various cardiovascular disease
US$ 28.71
US$ 21.36
US$ 20.13
US$ 25.03
US$ 22.11
US$ 23.42
US$ 26.71
)
